Neoantigen therapy is mainly through high-throughput gene sequencing and data analysis to discover individualized numerous somatic mutations in the patient's tumor, screen out mutations that may become neoantigens as targets, and load them on antigen-producing cells (APCs), thereby It has the effect of activating T cells to recognize a variety of new antigens, and then kill tumors.
The global Neoantigen Targeted Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Rising prevalence of malignancies and colon cancer, patient preference for targeted therapy, and increased risk of ovarian cancer among women are key factors for increasing market revenue.
This report aims to provide a comprehensive presentation of the global market for Neoantigen Targeted Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neoantigen Targeted Therapy.
Report Scope
The Neoantigen Targeted Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neoantigen Targeted Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neoantigen Targeted Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
BioNTech SE
Gritstone Bio
Genocea Biosciences
Moderna
Agenus
Immatics
Advaxis
Precision Biologics
Gilead Sciences
Cellular Biomedicine Group
Achilles Therapeutics
Merck and Co
Beijing Kati Medical Technology
Segment by Type
Off-the-shelf Neoantigen
Personalized Neoantigen
Segment by Application
Colorectal Cancer
Renal Cell Carcinoma
Non-Small Cell Lung cancer
Bone Cancer
Gynecological Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neoantigen Targeted Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Neoantigen Targeted Therapy 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Off-the-shelf Neoantigen
1.2.3 Personalized Neoantigen
1.3 麻豆原创 by Application
1.3.1 Global Neoantigen Targeted Therapy 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Colorectal Cancer
1.3.3 Renal Cell Carcinoma
1.3.4 Non-Small Cell Lung cancer
1.3.5 Bone Cancer
1.3.6 Gynecological Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neoantigen Targeted Therapy 麻豆原创 Perspective (2019-2030)
2.2 Neoantigen Targeted Therapy Growth Trends by Region
2.2.1 Global Neoantigen Targeted Therapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neoantigen Targeted Therapy Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Neoantigen Targeted Therapy Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Neoantigen Targeted Therapy 麻豆原创 Dynamics
2.3.1 Neoantigen Targeted Therapy Industry Trends
2.3.2 Neoantigen Targeted Therapy 麻豆原创 Drivers
2.3.3 Neoantigen Targeted Therapy 麻豆原创 Challenges
2.3.4 Neoantigen Targeted Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Targeted Therapy Players by Revenue
3.1.1 Global Top Neoantigen Targeted Therapy Players by Revenue (2019-2024)
3.1.2 Global Neoantigen Targeted Therapy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Neoantigen Targeted Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neoantigen Targeted Therapy Revenue
3.4 Global Neoantigen Targeted Therapy 麻豆原创 Concentration Ratio
3.4.1 Global Neoantigen Targeted Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Targeted Therapy Revenue in 2023
3.5 Neoantigen Targeted Therapy Key Players Head office and Area Served
3.6 Key Players Neoantigen Targeted Therapy Product Solution and Service
3.7 Date of Enter into Neoantigen Targeted Therapy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Neoantigen Targeted Therapy Breakdown Data by Type
4.1 Global Neoantigen Targeted Therapy Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Neoantigen Targeted Therapy Forecasted 麻豆原创 Size by Type (2025-2030)
5 Neoantigen Targeted Therapy Breakdown Data by Application
5.1 Global Neoantigen Targeted Therapy Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Neoantigen Targeted Therapy Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Neoantigen Targeted Therapy 麻豆原创 Size (2019-2030)
6.2 North America Neoantigen Targeted Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neoantigen Targeted Therapy 麻豆原创 Size by Country (2019-2024)
6.4 North America Neoantigen Targeted Therapy 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neoantigen Targeted Therapy 麻豆原创 Size (2019-2030)
7.2 Europe Neoantigen Targeted Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neoantigen Targeted Therapy 麻豆原创 Size by Country (2019-2024)
7.4 Europe Neoantigen Targeted Therapy 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Targeted Therapy 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Neoantigen Targeted Therapy 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neoantigen Targeted Therapy 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Neoantigen Targeted Therapy 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neoantigen Targeted Therapy 麻豆原创 Size (2019-2030)
9.2 Latin America Neoantigen Targeted Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neoantigen Targeted Therapy 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Neoantigen Targeted Therapy 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Targeted Therapy 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Neoantigen Targeted Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neoantigen Targeted Therapy 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Neoantigen Targeted Therapy 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BioNTech SE
11.1.1 BioNTech SE Company Detail
11.1.2 BioNTech SE Business Overview
11.1.3 BioNTech SE Neoantigen Targeted Therapy Introduction
11.1.4 BioNTech SE Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.1.5 BioNTech SE Recent Development
11.2 Gritstone Bio
11.2.1 Gritstone Bio Company Detail
11.2.2 Gritstone Bio Business Overview
11.2.3 Gritstone Bio Neoantigen Targeted Therapy Introduction
11.2.4 Gritstone Bio Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.2.5 Gritstone Bio Recent Development
11.3 Genocea Biosciences
11.3.1 Genocea Biosciences Company Detail
11.3.2 Genocea Biosciences Business Overview
11.3.3 Genocea Biosciences Neoantigen Targeted Therapy Introduction
11.3.4 Genocea Biosciences Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.3.5 Genocea Biosciences Recent Development
11.4 Moderna
11.4.1 Moderna Company Detail
11.4.2 Moderna Business Overview
11.4.3 Moderna Neoantigen Targeted Therapy Introduction
11.4.4 Moderna Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.4.5 Moderna Recent Development
11.5 Agenus
11.5.1 Agenus Company Detail
11.5.2 Agenus Business Overview
11.5.3 Agenus Neoantigen Targeted Therapy Introduction
11.5.4 Agenus Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.5.5 Agenus Recent Development
11.6 Immatics
11.6.1 Immatics Company Detail
11.6.2 Immatics Business Overview
11.6.3 Immatics Neoantigen Targeted Therapy Introduction
11.6.4 Immatics Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.6.5 Immatics Recent Development
11.7 Advaxis
11.7.1 Advaxis Company Detail
11.7.2 Advaxis Business Overview
11.7.3 Advaxis Neoantigen Targeted Therapy Introduction
11.7.4 Advaxis Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.7.5 Advaxis Recent Development
11.8 Precision Biologics
11.8.1 Precision Biologics Company Detail
11.8.2 Precision Biologics Business Overview
11.8.3 Precision Biologics Neoantigen Targeted Therapy Introduction
11.8.4 Precision Biologics Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.8.5 Precision Biologics Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Detail
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Neoantigen Targeted Therapy Introduction
11.9.4 Gilead Sciences Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.9.5 Gilead Sciences Recent Development
11.10 Cellular Biomedicine Group
11.10.1 Cellular Biomedicine Group Company Detail
11.10.2 Cellular Biomedicine Group Business Overview
11.10.3 Cellular Biomedicine Group Neoantigen Targeted Therapy Introduction
11.10.4 Cellular Biomedicine Group Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.10.5 Cellular Biomedicine Group Recent Development
11.11 Achilles Therapeutics
11.11.1 Achilles Therapeutics Company Detail
11.11.2 Achilles Therapeutics Business Overview
11.11.3 Achilles Therapeutics Neoantigen Targeted Therapy Introduction
11.11.4 Achilles Therapeutics Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.11.5 Achilles Therapeutics Recent Development
11.12 Merck and Co
11.12.1 Merck and Co Company Detail
11.12.2 Merck and Co Business Overview
11.12.3 Merck and Co Neoantigen Targeted Therapy Introduction
11.12.4 Merck and Co Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.12.5 Merck and Co Recent Development
11.13 Beijing Kati Medical Technology
11.13.1 Beijing Kati Medical Technology Company Detail
11.13.2 Beijing Kati Medical Technology Business Overview
11.13.3 Beijing Kati Medical Technology Neoantigen Targeted Therapy Introduction
11.13.4 Beijing Kati Medical Technology Revenue in Neoantigen Targeted Therapy Business (2019-2024)
11.13.5 Beijing Kati Medical Technology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
BioNTech SE
Gritstone Bio
Genocea Biosciences
Moderna
Agenus
Immatics
Advaxis
Precision Biologics
Gilead Sciences
Cellular Biomedicine Group
Achilles Therapeutics
Merck and Co
Beijing Kati Medical Technology
听
听
*If Applicable.
